AQSZF.US Aequus Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
0.0003 USD
Close of Nov 13, 2026
0.0002 0.0080
Market cap
USD 39.8K
P/E
-
P/B
32.78x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.

Is AQSZF.US undervalued?

Graham number

The Graham number of Aequus Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aequus Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Aequus Pharmaceuticals Inc yet.

Aequus Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aequus Pharmaceuticals Inc

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Full company profile